What is CeQur?
Established in 2008 and headquartered in Switzerland, CeQur is dedicated to the commercialization of sophisticated, user-friendly insulin-delivery devices. The company addresses a critical gap in the diabetes care market by focusing on technologies that enhance patient adherence and improve overall disease management. By prioritizing simplicity and efficacy, CeQur has positioned itself as a vital innovator in the medtech space, bridging the gap between complex clinical requirements and the practical, daily needs of patients living with diabetes. Their portfolio is designed to empower individuals to maintain better control over their health through reliable and intuitive medical hardware.
How much funding has CeQur raised?
CeQur has raised a total of $491.6M across 5 funding rounds:
Series A
$29.6M
Series B
$27M
Series C
$215M
Private Equity
$120M
Series E
$100M
Series A (2010): $29.6M with participation from Endeavour Vision and VI Partners
Series B (2013): $27M, investors not publicly disclosed
Series C (2015): $215M supported by Endeavour Vision, Arthurian Life Sciences, Woodford Investment Management, Ypsomed, Bank of Communications Schroder Fund Management Co. Ltd., Credit Suisse, Tandem Diabetes Care, GMS Capital, VI Partners, Kingdon Capital Management, and Federated Hermes Kaufmann Funds
Private Equity (2025): $120M, investors not publicly disclosed
Series E (2026): $100M, investors not publicly disclosed
Key Investors in CeQur
Endeavour Vision
Endeavour Vision is a leading investment advisory firm specializing in transformative healthcare technologies, particularly in medical devices and digital health. The firm empowers entrepreneurs to develop and commercialize innovative solutions that address critical unmet healthcare needs.
VI Partners
VI Partners is the longest-established Swiss VC firm, supporting innovative healthcare and technology companies for over two decades. They focus on fostering growth through strategic advisory and deep industry expertise.
Woodford Investment Management
Woodford Investment Management is a financial services firm that historically managed various investment funds, including the Woodford Patient Capital Trust, focusing on long-term growth opportunities in the life sciences and technology sectors.
What's next for CeQur?
With the successful completion of this major enterprise-level funding round, CeQur is well-positioned to accelerate its commercial expansion and deepen its market penetration. The strategic capital will likely be deployed to scale manufacturing capabilities, broaden distribution networks, and potentially fund further clinical validation of its next-generation delivery platforms. As the company transitions into this mature phase of its lifecycle, the focus will shift toward optimizing operational efficiency and solidifying its footprint in key international markets. Investors and industry observers will be closely monitoring how CeQur leverages this financial backing to maintain its competitive edge against established incumbents in the insulin delivery sector.
See full CeQur company page
